美国急诊科疑似阿片类药物过量就诊后的纳洛酮与丁丙诺啡处方情况:2019年8月至2021年4月
该回顾性队列分析利用Symphony Health综合数据仓库(涵盖5,800家医院和70,000家药房),纳入2019年8月4日至2021年4月3日148,966次急诊科阿片类药物过量就诊。结果显示,30天内至少1次纳洛酮和丁丙诺啡处方率分别为7.4%和8.5%;同期急诊科过敏反应就诊后肾上腺素处方率为48.9%。2020年4月26日至10月3日期间周均就诊量较2019年8月4日至2020年4月25日期间增加23.6%,之后回落至疫情前水平,2021年3月13日后再次上升。作者认为,临床医生错失了预防阿片类药物过量相关死亡的关键机会。
要点
- 148,966次急诊科阿片类药物过量就诊中,30天内纳洛酮处方率仅7.4%,丁丙诺啡处方率仅8.5%。
- 作为对照,急诊科过敏反应就诊后30天内肾上腺素处方率为48.9%,远高于纳洛酮处方率。
- 2020年4月26日至10月3日期间周均就诊量较2019年8月4日至2020年4月25日期间增加23.6%。
- 就诊量在2020年10月4日至2021年3月13日回落至疫情前水平,之后开始上升。
- 作者认为,急诊科阿片类药物过量就诊后处方率低,提示错失了预防过量相关死亡的关键机会。
适用人群与场景
- 2019年8月4日至2021年4月3日期间美国急诊科因阿片类药物过量就诊的患者。
研究设计与关键结果
- 研究类型:回顾性队列分析,使用Symphony Health综合数据仓库,涵盖5,800家医院和70,000家药房的数据。
- 样本量:纳入148,966次急诊科阿片类药物过量就诊。
- 主要终点:30天内至少1次纳洛酮处方率为7.4%,至少1次丁丙诺啡处方率为8.5%。
- 对照结果:急诊科过敏反应就诊后30天内至少1次肾上腺素处方率为48.9%。
- 就诊量趋势:2020年4月26日至10月3日期间周均就诊量较2019年8月4日至2020年4月25日期间增加23.6%;2020年10月4日至2021年3月13日回落至疫情前水平,之后开始上升。
证据类型、等级与局限
- 证据类型:回顾性队列分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,急诊科阿片类药物过量就诊后纳洛酮和丁丙诺啡处方率低,提示临床医生错失了预防阿片类药物过量相关死亡的关键机会。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: Nonfatal emergency department (ED) visits for opioid overdose are important opportunities to prescribe naloxone and buprenorphine, both of which can prevent future overdose-related mortality. We assessed the rate of this prescribing using national data from August 2019 to April 2021, a period during which US opioid overdose deaths reached record levels.
METHODS: We conducted a retrospective cohort analysis using Symphony Health's Integrated Dataverse, which includes data from 5,800 hospitals and 70,000 pharmacies. Of ED visits for opioid overdose between August 4, 2019, and April 3, 2021, we calculated the proportion with at least 1 naloxone prescription within 30 days and repeated this analysis for buprenorphine. To contextualize the naloxone prescribing rate, we calculated the proportion of ED visits for anaphylaxis with at least 1 prescription for epinephrine-another life-saving rescue medication-within 30 days.
RESULTS: Analyses included 148,966 ED visits for opioid overdose. Mean weekly visits increased 23.6% during the period between April 26, 2020 and October 3, 2020 compared with the period between August 4, 2019 to April 25, 2020. Visits declined to prepandemic levels between October 4, 2020 and March 13, 2021, after which visits began to rise. Naloxone and buprenorphine were prescribed within 30 days at 7.4% and 8.5% of the 148,966 visits, respectively. The naloxone prescribing rate (7.4%) was substantially lower than the epinephrine prescribing rate (48.9%) after ED visits for anaphylaxis.
CONCLUSION: Between August 4, 2019, and April 3, 2021, naloxone and buprenorphine were only prescribed after 1 in 13 and 1 in 12 ED visits for opioid overdose, respectively. Findings suggest that clinicians are missing critical opportunities to prevent opioid overdose-related mortality.
参考来源
- Chua KP, Dahlem CHY, Nguyen TD, et al. Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021. Ann Emerg Med. 2021. PMID: 34802772. doi:10.1016/j.annemergmed.2021.10.005
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。